Physician profile
Keith A Priddle
NPI 1235676099
$7,199.26
in general payments reported to CMS, 2019-2025
52 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,207 · 2022: $1,262 · 2023: $1,518 · 2024: $1,721 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697 · Education: $33.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,696.72 |
| Education | $33.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.10 | 2021-2025 | |
| Novo Nordisk INC | $1,268.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $769.71 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $516.46 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $463.59 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $305.91 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $226.91 | 2022-2025 | |
| Pfizer INC. | $199.18 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.17 | 2021-2025 | Jardiance, Ofev |
| Antares Pharma, INC. | $189.78 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Currax Pharmaceuticals LLC | $161.41 | 2022-2023 | Contrave, Nexletol, Nexlizet |
| Amgen INC. | $151.83 | 2022-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $105.78 | 2022-2025 | |
| Shield Therapeutics INC | $104.34 | 2022-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $94.40 | 2021-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Priddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.